About the Live Session

During the session, it is possible to ask questions directly to the company in Swedish or English. Answers will then be given in English. To participate in the session, you must become a member in the Facebook group " Aktier – Småbolagsjakten". Register your member application in good time to be sure to become a member. To do this, click the green "+ Gå med i grupp" button on the " Aktier – Småbolagsjakten" homepage. "Aktier – Småbolagsjakten" is the largest Facebook group in the Nordic region focusing on listed small companies. The group has over 37,000 members.

Financial advisor

Sedermera Fondkommission is the financial advisor to NeoDynamics in connection with the issue of units and the planned listing on Spotlight Stock Market. Nordnet Bank AB is acting as Selling Agent in the issue of units.

For further information about the IPO and the planned listing, please contact:

Sedermera Fondkommission

Telephone: +46 (0) 40-615 14 10

E-mail: info@sedermera.se

For further information about NeoDynamics, please contact:                            

Anna Eriksrud, CEO NeoDynamics AB (publ)

Telephone: +46 8 522 79 667

E-mail: anna.eriksrud@neodynamics.se

About NeoDynamics

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, NeoDynamics have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.